The call was about a baby—a 1.5-lb. baby who couldn’t breathe. The newborn needed help to prevent his underdeveloped lungs from collapsing.
When Charles G. Cochrane, MD, professor emeritus at The Scripps Research Institute (TSRI), picked up the phone, the infant was en route to San Diego’s Sharp Hospital. Cochrane rushed to the hospital in time to see the premature baby receive a dose of Surfaxin® (lucinactant), a drug he had spent two decades developing.